Skip to main content
. 2022 Jul 28;12:954814. doi: 10.3389/fcimb.2022.954814

Figure 5.

Figure 5

Lenalidomide inhibited HIV-1 reactivation in CD8-depleted PBMCs. CD8-depleted PBMCs were treated with TNF-α and LPS with or without lenalidomide for 5 days, or with the solvent control. (A, B), HIV core antigen was determined by flow cytometry in the PBMCs. (C), CA HIV RNA of CD8-depleted PBMCs was measured by RT-PCR. (D), Cytokine levels in the supernatants were determined by flow cytometry. *P < 0.05, **P < 0.01, *** P< 0.001, ****P < 0.0001.